StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Down 0.7 %
GLMD opened at $0.39 on Friday. Galmed Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $5.47. The company has a fifty day moving average of $0.37 and a 200-day moving average of $0.38. The stock has a market cap of $1.96 million, a PE ratio of -0.12 and a beta of 0.83.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings data on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- Stock Analyst Ratings and Canadian Analyst Ratings
- MarketBeat Week in Review – 5/20 – 5/24
- How to Calculate Inflation Rate
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- 3 Monster Growth Stocks to Buy Now
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
